Globus Medical (NYSE:GMED) Updates FY 2026 Earnings Guidance

Globus Medical (NYSE:GMED) updated its FY 2026 earnings guidance on Friday. The company provided EPS guidance of 4.400-4.50 for the period, compared to the consensus EPS estimate of 4.070. The company issued revenue guidance of $3.2 billion-$3.2 billion, compared to the consensus revenue estimate of $3.1 billion.

Globus Medical Stock Down 1.4%

Shares of GMED opened at $95.39 on Friday. The company has a 50 day moving average of $90.69 and a two-hundred day moving average of $76.48. The company has a market cap of $12.77 billion, a price-to-earnings ratio of 24.21, a price-to-earnings-growth ratio of 2.21 and a beta of 1.06. Globus Medical has a twelve month low of $51.79 and a twelve month high of $101.40.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Tuesday, February 24th. The medical device company reported $1.28 earnings per share for the quarter, topping analysts’ consensus estimates of $1.06 by $0.22. Globus Medical had a return on equity of 12.57% and a net margin of 18.30%.The firm had revenue of $826.42 million during the quarter, compared to analysts’ expectations of $803.29 million. During the same quarter last year, the firm earned $0.84 EPS. The business’s quarterly revenue was up 25.7% on a year-over-year basis. On average, sell-side analysts expect that Globus Medical will post 3.44 EPS for the current year.

Analysts Set New Price Targets

GMED has been the subject of several research analyst reports. Bank of America raised shares of Globus Medical from a “neutral” rating to a “buy” rating and increased their price objective for the company from $65.00 to $91.00 in a research report on Friday, November 7th. Needham & Company LLC raised their price target on shares of Globus Medical from $112.00 to $114.00 and gave the stock a “buy” rating in a report on Wednesday. Wells Fargo & Company lifted their price objective on shares of Globus Medical from $98.00 to $104.00 and gave the stock an “overweight” rating in a research note on Thursday. Royal Bank Of Canada upped their target price on Globus Medical from $92.00 to $100.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Finally, Canaccord Genuity Group lifted their price target on Globus Medical from $105.00 to $112.00 and gave the stock a “buy” rating in a research report on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $104.36.

Insider Buying and Selling at Globus Medical

In related news, EVP Kelly Huller sold 20,000 shares of Globus Medical stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $94.50, for a total transaction of $1,890,000.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Kyle Kline sold 3,594 shares of the business’s stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $101.10, for a total transaction of $363,353.40. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 54,136 shares of company stock valued at $5,001,033. Company insiders own 18.51% of the company’s stock.

Hedge Funds Weigh In On Globus Medical

Several institutional investors have recently modified their holdings of GMED. Advisory Services Network LLC purchased a new position in shares of Globus Medical in the 3rd quarter valued at about $26,000. EverSource Wealth Advisors LLC increased its holdings in shares of Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 197 shares during the period. Parallel Advisors LLC raised its position in Globus Medical by 45.1% during the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after buying an additional 173 shares during the last quarter. Headlands Technologies LLC lifted its holdings in shares of Globus Medical by 485.4% in the 2nd quarter. Headlands Technologies LLC now owns 761 shares of the medical device company’s stock valued at $45,000 after buying an additional 631 shares during the period. Finally, Hollencrest Capital Management purchased a new stake in Globus Medical during the fourth quarter worth about $51,000. Institutional investors and hedge funds own 95.16% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.